A Phase 1 interventional study of MEDI1814 for IV injection and MEDI1814 for Subcutaneous Injection in Mild-Moderate Alzheimer's Disease and Healthy Elderly, sponsored by AstraZeneca. Completed at 10 sites in United States. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-06-03.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Alzheimer Disease by AstraZeneca — none open to participants now, none under way, none of them phase 3. Alzheimer Disease · AstraZeneca.
Among the 24 studies in Alzheimer Disease by AstraZeneca, this one is the 9th largest by enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2014, is one of 15 in phase 1, and was the 18th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.
Browse Alzheimer Disease studies →None of the 24 studies in Alzheimer Disease by AstraZeneca is open now. The open studies under Alzheimer Disease, anywhere →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 55 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 5 · Phase 3 4
First in 2002; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is close to the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.
Median enrollment 52 across the 23 interventional studies, 2,400 across the 1 observational. Of the 24 that completed or were terminated, 5 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Alzheimer Disease by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, drug levels and effects on the body of 1 or 3 injections of MEDI1814, in people with mild to moderate Alzhiemer's Disease or healthy elderly people.
Inclusion Criteria Male and female (non child bearing potential) subjects Mild-moderate Alzheimer's Disease
Exclusion Criteria History or evidence of significant disease Presence of psychiatric disorder which would affect completion of the study Current serious or unstable illness
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.
Biological: MEDI1814 for IV injection
Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.
Biological: MEDI1814 for IV injection · Biological: IV Placebo
2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort
Biological: MEDI1814 for Subcutaneous Injection
2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort
Biological: Placebo for Subcutaneous Injection
Monoclonal antibody for IV Injection
Monoclonal antibody for subcutaneous injection
Placebo for IV injection
Subcutaneous Placebo Injection
Tolerability as Measured by Participant Withdrawal for an Adverse Event
Tolerability measured by participant withdrawal for an adverse event from randomization through end of study
Time frame: 4 months SAD; 7 months MAD
Area Under the Concentration Time Curve (AUC) Time 0 to t (28 Days After 1st Dose SAD and MAD and After 3rd Dose in MAD, Day 57)
Area Under the Concentration time curve (AUC) time 0 to t; calculated from Just prior to dose administration start to 28th day after dose (pre infusion, during infusion, 1,2,4,8,24,48 hr 7, 14, 21, and 28 day)
Time frame: 1 month
Maximum Plasma Concentration (Cmax) of Medi1814
Maximum plasma concentration (Cmax) of Medi1814 during 28 day period after dose administration start (prior to dosing, during infusion, 1, 2, 4, 8, 24, 48 hr, 7, 14,21, and 28 days)
Time frame: 1 month
Mean Termination Half Life (t 1/2) of Medi1814
Mean termination half life (t 1/2) of Medi1814 during 28 day period after dose administration start (SAD Day 1 dose, MAD 3rd dose)
Time frame: 1 month
Biomarkers: Amyloid-beta in Cerebral Spinal Fluid (Two Amyloid Bets Peptides of 40 and 42 Amino Acids Were Assessed)
Biomarkers: Amyloid-beta in cerebral spinal fluid, mean percent change from baseline
Time frame: Day 29 in SAD; Day 85 in MAD
Biomarker: Total Amyloid-beta 1-42 in Plasma
Biomarker: Total Amyloid-beta 1-42 in plasma, mean percent change from baseline
Time frame: Day 29 in SAD; Day 85 in MAD
Medi1814 Concentration in CSF Samples
Medi1814 concentration in CSF Samples; number of sampled subjects with a value above the lower limit of quantification
Time frame: SAD Day 29; MAD Day 85
Immunogenicity: Anti-drug Antibody Titer
Immunogenicity: Anti-drug antibody titer, subject counted if titer 50 or greater on any test, else 0 if all \<50
Time frame: 4 months SAD (6 tests over 4 months; week 1, 2, 4, 8, 12, 16); 7 months MAD (7 monthly tests)
261 screening visits in 193 individuals were required to randomize 45 subjects into 6 Single Ascending Dose (SAD) cohorts and 32 subjects into 4 Multiple Ascending Dose (MAD) cohorts.
| Milestone | Placebo: SAD | Medi1814 25 mg IV: SAD | Medi1814 100 mg IV: SAD | Medi1814 300 mg IV: SAD | Medi1814 900 mg IV: SAD | Medi1814 1800 mg IV: SAD | Medi1814 100 mg SC: SAD | Placebo: MAD | Medi1814 300 mg IV: MAD | Medi1814 900 mg IV: MAD | Medi1814 1800 mg IV: MAD | Medi1814 200 mg SC: MAD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 12 | 3 | 6 | 6 | 6 | 6 | 6 | 0 | 0 | 0 | 0 | 0 |
| Completed | 12 | 3 | 6 | 5 | 6 | 6 | 5 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo: SAD | Medi1814 25 mg IV: SAD | Medi1814 100 mg IV: SAD | Medi1814 300 mg IV: SAD | Medi1814 900 mg IV: SAD | Medi1814 1800 mg IV: SAD | Medi1814 100 mg SC: SAD | Placebo: MAD | Medi1814 300 mg IV: MAD | Medi1814 900 mg IV: MAD | Medi1814 1800 mg IV: MAD | Medi1814 200 mg SC: MAD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 6 | 6 | 6 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tolerability measured by participant withdrawal for an adverse event from randomization through end of study
| Participants | Placebo: SAD | Medi1814 25 mg IV: SAD | Medi1814 100 mg IV: SAD | Medi1814 300 mg IV: SAD | Medi1814 900 mg IV: SAD | Medi1814 1800 mg IV: SAD | Medi1814 100 mg SC : SAD | Placebo: MAD | Medi1814 300 mg IV: MAD | Medi1814 900 mg IV: MAD | Medi1814 1800 mg IV: MAD | Medi1814 200 mg SC: MAD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tolerability as Measured by Participant Withdrawal for an Adverse Event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Area Under the Concentration time curve (AUC) time 0 to t; calculated from Just prior to dose administration start to 28th day after dose (pre infusion, during infusion, 1,2,4,8,24,48 hr 7, 14, 21, and 28 day)
| ng x day/mL | Medi1814 25 mg IV: SAD | Medi1814 100 mg IV: SAD | Medi1814 300 mg IV: SAD | Medi1814 900 mg IV: SAD | Medi1814 1800 mg IV: SAD | Medi1814 100 mg SC: SAD | Medi1814 300 mg IV: MAD | Medi1814 900 mg IV: MAD | Medi1814 1800 mg IV: MAD | Medi1814 200 mg SC: MAD |
|---|---|---|---|---|---|---|---|---|---|---|
| First Dose (day 1-29) | 80.5 ± 61.1 | 455 ± 19.7 | 1550 ± 26.3 | 4040 ± 28.0 | 4420 ± 30.7 | 120 ± 51.9 | 710 ± 24.2 | 1690 ± 75.3 | 4490 ± 24.2 | 162 ± 69.2 |
| Third dose (day 57-85) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 1150 ± 37.9 | 2680 ± 74 | 7150 ± 27.3 | 134 ± 57.0 |
Maximum plasma concentration (Cmax) of Medi1814 during 28 day period after dose administration start (prior to dosing, during infusion, 1, 2, 4, 8, 24, 48 hr, 7, 14,21, and 28 days)
| ng/ml | Medi1814 25 mg IV: SAD | Medi1814 100 mg IV: SAD | Medi1814 300 mg IV: SAD | Medi1814 900 mg IV: SAD | Medi1814 1800 mg IV: SAD | Medi1814 100 mg SC: SAD | Medi1814 300 mg IV: MAD | Medi1814 900 mg IV: MAD | Medi1814 1800 mg IV: MAD | Medi1814 200 mg SC: MAD |
|---|---|---|---|---|---|---|---|---|---|---|
| First dose (day 1-29) | 10.2 ± 42.7 | 38.7 ± 30.9 | 102 ± 14.7 | 341 ± 19.3 | 424 ± 36.1 | 3.59 ± 51.4 | 83.9 ± 22.3 | 172 ± 77.2 | 496 ± 24.4 | 10.1 ± 81.4 |
| Third dose (day 57-85) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 96.7 ± 38.3 | 185 ± 110 | 536 ± 32.3 | 7.56 ± 38.5 |
Mean termination half life (t 1/2) of Medi1814 during 28 day period after dose administration start (SAD Day 1 dose, MAD 3rd dose)
| days | Medi1814 25 mg IV: SAD | Medi1814 100 mg IV: SAD | Medi1814 300 mg IV: SAD | Medi1814 900 mg IV: SAD | Medi1814 1800 mg IV: SAD | Medi1814 100 mg SC: SAD | Medi1814 300 mg IV: MAD | Medi1814 900 mg IV: MAD | Medi1814 1800 mg IV: MAD | Medi1814 200 mg SC: MAD |
|---|---|---|---|---|---|---|---|---|---|---|
| First dose (day 1-29) | 17.2 ± 0.94 | 17.0 ± 2.16 | 17.1 ± 2.78 | 19.0 ± 2.23 | 18.3 ± 7.69 | 19.8 ± 3.56 | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Third dose (day 57-85) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 14.2 ± 1.86 | 16.2 ± 1.61 | 20.4 ± 5.38 | 16.4 ± 3.29 |
Biomarkers: Amyloid-beta in cerebral spinal fluid, mean percent change from baseline
| % change | Placebo: SAD | Medi1814 25 mg IV: SAD | Medi1814 100 mg IV: SAD | Medi1814 300 mg IV: SAD | Medi1814 900 mg IV: SAD | Medi1814 1800 mg IV: SAD | Medi1814 100 mg SC: SAD | Placebo: MAD | Medi1814 300 mg IV: MAD | Medi1814 900 mg: MAD | Medi1814 1800 mg IV: MAD | Medi1814 200 mg SC: MAD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total amyloid-beta 1-40 | 122.9 ± 426.51 | -15.9 ± 20.57 | -21.0 ± 19.57 | 8.72 ± 31.69 | 2.0 ± 29.21 | 10.2 ± 98.14 | -14.6 ± 23.69 | 4.96 ± 90.19 | 638.5 ± 1054.28 | -17.9 ± 34.08 | -36.96 ± 46.82 | 38.06 ± 47.51 |
| Total amyloid-beta 1-42 | 25.3 ± 100.71 | 52.0 ± 104.35 | 41.7 ± 38.68 | 192.8 ± 127.96 | 414.7 ± 292.18 | 376.1 ± 295.92 | 5.87 ± 24.52 | -29.4 ± 55.90 | 633.6 ± 471.79 | 197.5 ± 115.25 | 915.5 ± 1361.86 | 87.8 ± 124.68 |
| Free amyloid-beta 1-42 | 28.6 ± 113.70 | -33.9 ± 13.98 | -54.3 ± 39.96 | -57.2 ± 55.80 | -81.65 ± 21.67 | -15.2 ± 189.05 | -19.0 ± 17.69 | -2.5 ± 62.66 | 11.6 ± 167.59 | -96.3 ± 2.26 | -95.0 ± 1.88 | -57.7 ± 29.76 |
Biomarker: Total Amyloid-beta 1-42 in plasma, mean percent change from baseline
| % change | Placebo: SAD | Medi1814 25 mg IV: SAD | Medi1814 100 mg IV: SAD | Medi1814 300 mg IV: SAD | Medi1814 900 mg IV: SAD | Medi1814 1800 mg IV: SAD | Medi1814 100 mg SC: SAD | Placebo: MAD | Medi1814 300 mg IV: MAD | Medi1814 900 mg IV: MAD | Medi1814 1800 mg IV: MAD | Medi1814 200 mg SC: MAD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomarker: Total Amyloid-beta 1-42 in Plasma | 19.6 ± 34.51 | 40132.5 ± 4379.93 | 41107.0 ± 43509.89 | 46667.9 ± 29628.09 | 78534.5 ± 22773.96 | 44050.9 ± 15776.40 | 45404.0 ± 1808.13 | -32.0 ± 45.65 | 30272.4 ± 14834.80 | 84652.8 ± 44649.16 | 43415.3 ± 13760.07 | 97140.1 ± 34151.47 |
Medi1814 concentration in CSF Samples; number of sampled subjects with a value above the lower limit of quantification
| Participants | Medi1814 25 mg IV: SAD | Medi1814 100 mg IV: SAD | Medi1814 300 mg IV: SAD | Medi1814 900 mg IV: SAD | Medi1814 1800 mg IV: SAD | Medi1814 100 mg SC: SAD | Medi1814 300 mg IV: MAD | Medi1814 900 mg IV: MAD | Medi1814 1800 mg IV: MAD | Medi1814 200 mg SC: MAD |
|---|---|---|---|---|---|---|---|---|---|---|
| First dose (day 1-29) | 0 ± 0.94 | 0 ± 2.16 | 1 ± 2.78 | 2 ± 2.23 | 4 ± 7.69 | 0 ± 3.56 | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Third dose (day 57-85) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 1 ± 1.86 | 5 ± 1.61 | 6 ± 5.38 | 0 ± 3.29 |
Immunogenicity: Anti-drug antibody titer, subject counted if titer 50 or greater on any test, else 0 if all \<50
| Participants | Placebo: SAD | Medi1814 25 mg IV: SAD | Medi1814 100 mg IV: SAD | Medi1814 300 mg IV: SAD | Medi1814 900 mg IV: SAD | Medi1814 1800 mg IV: SAD | Medi1814 100 mg SC : SAD | Placebo: MAD | Medi1814 300 mg IV: MAD | Medi1814 900 mg IV: MAD | Medi1814 1800 mg IV: MAD | Medi1814 200 mg SC: MAD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunogenicity: Anti-drug Antibody Titer | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over From baseline until day 113 (4 months) in SAD Study Part 1; From baseline until day 169 (7 months) in MAD Study Part 2. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo: SAD | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Medi1814 25 mg IV: SAD | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Medi1814 100 mg IV: SAD | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Medi1814 300 mg IV: SAD | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Medi1814 900 mg IV: SAD | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Medi1814 1800 mg IV: SAD | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Medi1814 100 mg SC: SAD | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Placebo: MAD | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Medi1814 300 mg IV: MAD | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Medi1814 900 mg IV: MAD | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Medi1814 1800 mg IV: MAD | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Medi1814 200 mg SC: MAD | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Event | Placebo: SAD | Medi1814 25 mg IV: SAD | Medi1814 100 mg IV: SAD | Medi1814 300 mg IV: SAD | Medi1814 900 mg IV: SAD | Medi1814 1800 mg IV: SAD | Medi1814 100 mg SC: SAD | Placebo: MAD | Medi1814 300 mg IV: MAD | Medi1814 900 mg IV: MAD | Medi1814 1800 mg IV: MAD | Medi1814 200 mg SC: MAD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal pain upperGastrointestinal disorders | 0/12 | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/6 | 0/6 | 2/6 | 0/6 |
| DizzinessNervous system disorders | 1/12 | 0/3 | 0/6 | 0/6 | 2/6 | 0/6 | 0/6 | 0/8 | 1/6 | 0/6 | 0/6 | 0/6 |
| HeadacheNervous system disorders | 2/12 | 1/3 | 1/6 | 0/6 | 0/6 | 1/6 | 1/6 | 0/8 | 1/6 | 0/6 | 1/6 | 1/6 |
| Sinus bradycardiaCardiac disorders | 0/12 | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/6 | 1/6 | 0/6 | 0/6 |
| VertigoEar and labyrinth disorders | 0/12 | 0/3 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/8 | 0/6 | 0/6 | 0/6 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/6 | 1/6 | 1/6 | 1/6 |
| PyrexiaGeneral disorders | 0/12 | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/6 | 1/6 | 0/6 | 0/6 |
| FatigueGeneral disorders | 0/12 | 0/3 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/8 | 0/6 | 0/6 | 0/6 | 0/6 |
| Injection site painGeneral disorders | 0/12 | 0/3 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/8 | 0/6 | 0/6 | 0/6 | 0/6 |
| NasopharyngitisInfections and infestations | 0/12 | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 1/6 | 0/6 | 0/6 | 0/6 |
All randomized subjects, Safety Analysis Population
| Age, Continuous(years) | Placebo: SAD | Medi1814 25 mg IV: SAD | Medi1814 100 mg IV: SAD | Medi1814 300 mg IV: SAD | Medi1814 900 mg IV: SAD | Medi1814 1800 mg IV: SAD | Medi1814 100 mg SC: SAD | Placebo: MAD | Medi1814 300 mg IV: MAD | Medi 1814 900 mg IV: MAD | Medi1814 1800 mg IV: MAD | Medi1814 200 mg SC: MAD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 66.3 ± 7.22 | 74.0 ± 8.89 | 66.8 ± 1.94 | 69.0 ± 6.10 | 71.8 ± 5.15 | 64.8 ± 5.91 | 69.3 ± 4.84 | 70.0 ± 5.90 | 71.7 ± 6.62 | 70.8 ± 6.62 | 62.5 ± 6.16 | 69.3 ± 8.71 | 68.5 ± 6.55 |
| Sex: Female, Male(Participants) | Placebo: SAD | Medi1814 25 mg IV: SAD | Medi1814 100 mg IV: SAD | Medi1814 300 mg IV: SAD | Medi1814 900 mg IV: SAD | Medi1814 1800 mg IV: SAD | Medi1814 100 mg SC: SAD | Placebo: MAD | Medi1814 300 mg IV: MAD | Medi 1814 900 mg IV: MAD | Medi1814 1800 mg IV: MAD | Medi1814 200 mg SC: MAD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 7 | 0 | 6 | 5 | 4 | 1 | 3 | 5 | 3 | 2 | 3 | 5 | 44 |
| Male | 5 | 3 | 0 | 1 | 2 | 5 | 3 | 3 | 3 | 4 | 3 | 1 | 33 |
| Ethnicity (NIH/OMB)(Participants) | Placebo: SAD | Medi1814 25 mg IV: SAD | Medi1814 100 mg IV: SAD | Medi1814 300 mg IV: SAD | Medi1814 900 mg IV: SAD | Medi1814 1800 mg IV: SAD | Medi1814 100 mg SC: SAD | Placebo: MAD | Medi1814 300 mg IV: MAD | Medi 1814 900 mg IV: MAD | Medi1814 1800 mg IV: MAD | Medi1814 200 mg SC: MAD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 0 | 5 | 4 | 1 | 6 | 1 | 5 | 5 | 5 | 6 | 6 | 52 |
| Not Hispanic or Latino | 4 | 3 | 1 | 2 | 5 | 0 | 5 | 3 | 1 | 1 | 0 | 0 | 25 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo: SAD | Medi1814 25 mg IV: SAD | Medi1814 100 mg IV: SAD | Medi1814 300 mg IV: SAD | Medi1814 900 mg IV: SAD | Medi1814 1800 mg IV: SAD | Medi1814 100 mg SC: SAD | Placebo: MAD | Medi1814 300 mg IV: MAD | Medi 1814 900 mg IV: MAD | Medi1814 1800 mg IV: MAD | Medi1814 200 mg SC: MAD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 2 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| White | 10 | 1 | 6 | 4 | 5 | 6 | 5 | 8 | 5 | 6 | 6 | 5 | 67 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mini Mental State Exam (MMSE)(MMSE score) | Placebo: SAD | Medi1814 25 mg IV: SAD | Medi1814 100 mg IV: SAD | Medi1814 300 mg IV: SAD | Medi1814 900 mg IV: SAD | Medi1814 1800 mg IV: SAD | Medi1814 100 mg SC: SAD | Placebo: MAD | Medi1814 300 mg IV: MAD | Medi 1814 900 mg IV: MAD | Medi1814 1800 mg IV: MAD | Medi1814 200 mg SC: MAD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 21.8 ± 3.02 | 22.0 ± 2.65 | 22.3 ± 3.27 | 22.5 ± 3.73 | 22.2 ± 2.99 | 21.0 ± 2.00 | 23.2 ± 2.04 | 22.1 ± 2.48 | 19.8 ± 2.58 | 20.2 ± 1.72 | 20.0 ± 2.45 | 22.5 ± 2.59 | 21.6 ± 3.07 |
Ran from Feb 2014 to primary completion in Sep 2016, 31 months.
Results were first posted in Jun 2019, 2 years 8 months after primary completion.
Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 31 months is above that.
Counting every sponsor, half of 234 studies reached it within 17 months; a quarter within 7 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.